Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846

阿帕蒂尼 医学 内科学 不利影响 蛋白尿 胃肠病学 食欲不振 临床终点 化疗 外科 肉瘤 软组织肉瘤 软组织 临床试验 病理 肾
作者
Xinyue Liu,Jin Xu,Feng Li,Zhichao Liao,Zhiwu Ren,Lei Zhu,Yehui Shi,Gang Zhao,Xu Bai,Jun Zhao,Ruwei Xing,Sheng Teng,Yun Yang,Jilong Yang
出处
期刊:Biomedicine & Pharmacotherapy [Elsevier BV]
卷期号:122: 109587-109587 被引量:15
标识
DOI:10.1016/j.biopha.2019.109587
摘要

There is no standard treatment for stage IV soft tissue sarcoma (STS) after the failure of Adriamycin-based chemotherapy. This phase II study (NCT03121846) assessed the efficacy and safety of apatinib (YN968D1), a new tyrosine kinase inhibitor that targets VEGFR-2, for patients with stage IV STS after chemotherapy failure.Forty-two subjects with stage IV STSs who had failed chemotherapy and who received Apatinib were recruited between September 2015 and February 2018. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were the PFS rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12. Treatment-related adverse effects (AEs) were evaluated.Forty-two subjects were evaluated for AEs and 38 subjects were evaluated for efficacy. At 12 weeks, the PFR, ORR, and DCR were 70%, 26.32% (10/38), and 86.84% (33/38), respectively. Regarding overall responses, the ORR and DCR were 23.68% (9/38) and 57.89% (22/38), respectively. The median PFS was 7.87 months, and the median overall survival (OS) was 17.55 months. The most common AEs included hypertension (n = 18, 42.86%), hand-foot-skin reaction (n = 15, 35.71%), apositia (n = 13, 30.95%), and proteinuria (n = 11, 26.19%). No subjects had grade 4 AEs and 11 subjects (26.19%) experienced grade 3 AEs, mainly hypertension, hand-foot-skin reaction, proteinuria, apositia, fatigue, pain, and dysgeusia. Notably, the subjects who experienced hypertension, hand-foot-skin reaction, or proteinuria had significantly longer OS than those without these AEs (P = 0.0003).With the largest Chinese STS cohort to date, we report that apatinib show good efficacy in advanced STS subjects with significant higher ORR and some adverse events may predict prognosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Asurary完成签到 ,获得积分10
1秒前
天然完成签到,获得积分20
1秒前
1秒前
zz完成签到,获得积分10
2秒前
柳炳发布了新的文献求助10
2秒前
田様的应助被玩家666采纳,获得10
2秒前
3秒前
领导范儿的应助被芋泥好暖椰y采纳,获得10
4秒前
4秒前
酷波er的应助被昏睡的金毛采纳,获得10
4秒前
4秒前
KRYSTAL完成签到,获得积分10
4秒前
5秒前
5秒前
光亮的元容完成签到,获得积分10
6秒前
大吉大利完成签到,获得积分10
6秒前
asdfqwer发布了新的文献求助10
6秒前
Zen完成签到,获得积分10
6秒前
大模型的应助被小沈采纳,获得10
6秒前
7秒前
汉堡包的应助被medsci采纳,获得10
7秒前
秋风的应助被小笨蛋采纳,获得10
7秒前
轩辕幻香发布了新的文献求助200
7秒前
纤花语完成签到 ,获得积分10
7秒前
8秒前
9秒前
哥哥完成签到,获得积分10
9秒前
Echo发布了新的文献求助40
10秒前
lan完成签到,获得积分20
10秒前
共享精神的应助被孙思琪采纳,获得10
10秒前
10秒前
11秒前
11秒前
chenyu1231发布了新的文献求助10
12秒前
过过过发布了新的文献求助10
12秒前
pure发布了新的文献求助10
12秒前
搜集达人的应助被nyr采纳,获得10
12秒前
12秒前
柠檬完成签到,获得积分10
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193684
求助须知:如何正确求助?哪些是违规求助? 9579855
关于积分的说明 21867890
捐赠科研通 7793357
什么是DOI,文献DOI怎么找? 3437385
关于科研通互助平台的介绍 2560783
邀请新用户注册赠送积分活动 2484193